Tvardi Therapeutics Inc. Ordinary Shares TVRD 深 沪
等待开盘 12-03 09:30:00 美东时间
3.75
-0.160
-4.09%
华盛通- 最 高3.99
- 今 开3.95
- 成交量 13.87万股
- 最 低 3.74
- 昨 收 3.91
- 总市值 3517.99万
- 52周最高 43.65
- 市盈率 静 --
- 换手率 1.48%
- 52周最低 3.74
- 委 比 50.74%
- 总股本 938.13万
- 历史最高 1067.292
- 量 比 1.27
- 振 幅 6.39%
- 历史最低 3.74
- 每 手 1
- 风险率 9.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you ...
11-30 22:46
Tvardi Therapeutics Q3 EPS $(0.59) Beats $(0.92) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.92) by 35.8 percent.
11-14 05:32
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Tvardi Therapeutics Said Preliminary Data From Phase 2 REVERT Trial of TTI-101 In Idiopathic Pulmonary Fibrosis Show That The Study Did Not Meet Its Goals
The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or in addition to nintedanib (OFEV®) in patients with IPF. The study was designed to assess
10-13 19:32
Tvardi Therapeutics GAAP EPS of -$1.00
Tvardi Therapeutics press release (NASDAQ:TVRD): Q2 GAAP EPS of -$1.00. Cash, cash equivalents and short-term investments as of June 30, 2025, were $41.0 million, as compared to $31.6 million as of De...
08-15 04:58
Tvardi Therapeutics Q2 EPS $(1.00) Misses $(0.58) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.58) by 73.01 percent.
08-15 04:33
Cantor Fitzgerald Initiates Coverage On Tvardi Therapeutics with Overweight Rating, Announces Price Target of $52
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces Price Target of $52.
07-11 20:00
Coinbase, Datadog, Tvardi, CF, Conagra: Trending by Analysts
Analysts are intrested in these 5 stocks: ( ($COIN) ), ( ($DDOG) ), ( ($TVRD) )...
06-14 17:01
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
Piper Sandler Initiates Coverage On Tvardi Therapeutics with Overweight Rating, Announces Price Target of $78
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces Price Target of $78.
06-12 17:27
